English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, May 13, 2022
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文
祝賀!國際頂級醫學期刊《自然-醫學》同時發表兩篇關於華領醫藥全球首創糖尿病新藥多格列艾汀的III期研究結果的同行評議論文
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine
Thursday, March 17, 2022
华领医药公布2021年全年业绩
華領醫藥公佈2021年全年業績
Hua Medicine Announces 2021 Annual Results
Sunday, September 26, 2021
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin
研究者公佈有關多格列艾汀糖尿病緩解的重要研究
研究者公布有关多格列艾汀糖尿病缓解的重要研究
Wednesday, September 15, 2021
华领医药与国药控股签署供应链战略合作协议 加速商业化布局

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575